We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


N4 Pharma Announces Collaboration With SRI To Target and Treat Cells in the Human Body That Have Been Previously Unreachable

Credit: iStock.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

N4 Pharma Plc (AIM: N4P), the company developing Nuvec®, a novel delivery system designed to carry nucleotides to be developed as cancer treatments and vaccines, has entered into a research collaboration agreement with SRI, an independent nonprofit research institute based in Silicon Valley, California, to combine Nuvec with SRI’s proprietary FOX Three Molecular Guidance System™ (MGS) with the aim of co-marketing the combined technology. The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec® in order to increase intracellular delivery to specific target cells. On the back of the combined technology, N4 Pharma and SRI will work collaboratively to develop and pursue new business opportunities.


SRI's MGS technology is designed to overcome cellular barriers that prevent intracellular delivery of large molecule biotherapeutics. The system uses proprietary technology that enables the delivery of macromolecular payloads to the target cell and then on to subcellular locations within those cells. SRI has demonstrated that the MGS technology can deliver more than a dozen types of payloads - from functional enzymes, antibodies, and nucleic acids (including siRNA, ASOs, and DNA) to liposomes and nanoparticles - to targeted, intracellular molecular-target locations previously considered unreachable, and therefore, untreatable. 


N4 Pharma’s silica nanoparticle Nuvec has an irregular surface structure that simply and effectively traps and protects the siRNA, RNA and DNA to help delivery to the cell membrane. Once inside the cell, the siRNA/RNA/DNA is released to enter the cellular machinery, resulting in the desired pathway response - protein silencing, protein transcription, or other immuno-response. 

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Together, the combined technology holds the potential to pave the way for targeted, effective treatments and to help realize the full potential of precision healthcare. 


Kathlynn Brown, President of SRI’s Biosciences division, commented: “We’re excited to work with N4 Pharma to advance nucleic acid therapies and expand the number of applications of their Nuvec nanoparticle technology using the FOX Three Platform. The key properties of Nuvec, including preventing enzymatic breakdown of nucleotides and large surface area allowing multiple copy number of cargo, together with the targeting provided by MGS, may significantly enhance the use of nucleotide therapies. This strategic partnership marks an exciting journey towards expanding treatment possibilities and transforming the landscape of biomedicine.”


Nigel Theobald, Chief Executive Officer of the Company, commented: We are delighted to be working with SRI and to have entered into this collaboration agreement. Combining our technologies successfully will lead to working with major pharma companies in the fields of oncology and vaccines with the exciting potential to develop novel products. SRI collaborates with a broad range of strategic partners from small and virtual biotechnology companies to top 10 pharmaceutical companies and other leading industry partners, which will give us unparalleled access to potential commercial partners on the back of any successful combined technology resulting from our research. This marks an exciting new chapter for N4 Pharma and I look forward to providing further updates as the research work progresses, as well as on our other work streams such as oral applications of Nuvec® and the development of ECP105 for an orphan indication with Nanogenics.”


The SRI biosciences group integrates basic biomedical research with drug and diagnostics discovery, and preclinical and clinical development. It has advanced more than 200 drugs to clinical trials, and 25 have reached the market. The division is focused on novel platforms and programs in a variety of therapeutic areas targeting high unmet medical needs.